Speedy BSE test pushes up Proteus shares
Friday 21 February 1997
Shield Diagnostics' share price was also strong, rising 80p to 416.5p, after it revealed a research tie-up with Abbott Laboratories, the US pharmaceuticals group. However, investors reacted negatively to news that plans by Phytopharm to develop a plant-based cure for eczema would be delayed by around two years. The shares fell 23p to 185.5p.
Proteus said Enfer Scientific, an Irish licensee, had produced a high- throughput test for BSE based on a reagent produced by the British firm which had been validated by the Irish Department of Agriculture. David Gration, chairman, said the department's agricultural veterinary research laboratory was "happy to validate that this test does successfully discriminate between positive and negative BSE carcasses".
The post mortem test was capable of processing 1,000 samples at a time and could be used in slaughterhouses, he said. Proteus went through a bad patch last year after raising pounds 9.5m in a rights issue and seeing then chief executive, Jurek Sikorski, resign soon after.
But Mr Gration said Proteus had signed a deal with Enfer which would net Proteus 12.5 per cent of any revenues earned from the test, which analysts believe could give the company income running into seven figures.
Shield, meanwhile, said it had signed an exploratory research agreement with the diagnostics division of Abbott Laboratories. This would give it access to Abbott's instruments, reagents and training in developing new hospital diagnostic tests, the company said.
The problems of Phytopharm, whose technology is based on Chinese herbal remedies, concern its Zemaphyte drug for severe atopic eczema, a skin complaint. UK approval for the product, currently in phase three trials with 150 patients, will be delayed for around 18 months after US tests begin in September, according to Richard Dixey, chief executive.
This was due to concerns expressed by the British Medicines Control Agency.
But Mr Dixey played down the delays, saying they wouldhelp improve the chances for the drug, given that regulators on both sides of the Atlantic were now in closer liaison and the company had a clearer target to aim for.
- 1 10 ways we damage our teeth – without realising
- 2 Fifa corruption arrests: Nike reported to be 'multinational sportswear company' at centre of bribery claims over Brazil shirt deal
- 3 Facebook Messenger sends 'creepily' precise location data, as revealed by Marauders Map Chrome extension
- 4 Bahar Mustafa: Goldsmiths Students' Union diversity officer to keep her job after vote of no confidence petition fails
- 5 Photo of wedding guest proposing to girlfriend in front of bride and groom goes viral
Hopes raised for treatment of severe amnesia after scientists retrieve lost memory – using light
Playboy model April Summers speaks out about being a victim of a voyeuristic sex crime
Poorest part of London is wealthier than the richest parts of Northern Ireland and Wales
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
How to live to be really old
EU referendum: David Cameron's rules are a 'democratic disgrace', says French-born Scottish politician set to be denied a vote
SNP fury as HS2 finds 'no business case' for taking fast train service to Scotland
Australian man punched in the face for defending Muslim women from abuse on train
A nation of inequality: How the UK is failing to feed its most vulnerable people
EU referendum: David Cameron to deny EU migrants and under-18s the chance to vote
David Starkey 'tells Amal Clooney to shut up and stop over-promoting human rights'
iJobs Money & Business
£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...
£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...
£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...
£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...